Added to YB: 2026-05-28
Pitch date: 2026-05-26
COIL.L [bullish]
Coiled Therapeutics plc
Author Info
No bio for this author
Company Info
Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally.
Coiled Therapeutics
COIL.L: Phase I AO-252 oral TACC3 inhibitor shows 80% Clinical Benefit Rate in heavily pre-treated solid tumors (5+ prior lines); clean safety, no MTD yet. Blood-brain barrier penetrant, dual mechanism (direct kill + immune activation via STING). Expansion cohorts (ovarian/prostate) data H2 2026. J&J paid $3B for comparable Phase I/II prostate asset (Halda). Proven team (built Biomea to $1B+ cap). £40M mkt cap vs $20B+ PARP/CDK4/6 market. Partnering/M&A catalyst ahead.
Read full article (15 min)